Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer
- 7 November 2023
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (1) , 69-81
Abstract
Tamoxifen is the frontline therapeutic agent for the estrogen receptor-positive (ER + ) subtype of breast cancer patients, which accounts for 70–80% of total breast cancer incidents. However, clinical resistance to tamoxifen has become increasingly common, highlighting the need to identify the underlying cellular mechanisms. In our study, we employed a genome-scale CRISPR-Cas9 loss-of-function screen and validation experiments to discover that Tafazzin (TAZ), a mitochondrial transacylase, is crucial for maintaining the cellular sensitivity of ER+ breast cancer cells to tamoxifen and other chemotherapies. Mechanistically, we found that cardiolipin, whose synthesis and maturation rely on TAZ, is required to maintain cellular sensitivity to tamoxifen. Loss of metabolic enzymatic activity of TAZ causes ERα downregulation and therapy resistance. Interestingly, we observed that TAZ deficiency also led to the upregulation of lysophosphatidylcholine (LPC), which in turn suppressed ERα expression and nuclear localization, thereby contributing to tamoxifen resistance. LPC is further metabolized to lysophosphatidic acid (LPA), a bioactive molecule that supports cell survival. Thus, our findings suggest that the depletion of TAZ promotes tamoxifen resistance through an LPC-LPA phospholipid synthesis axis, and targeting this lipid metabolic pathway could restore cell susceptibility to tamoxifen treatment.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81772981, 81972462)
This publication has 57 references indexed in Scilit:
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Role of the autotaxin–lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Molecular Profiling for Breast Cancer: A Comprehensive ReviewBiomarkers in Cancer, 2013
- Biological mechanisms and clinical implications of endocrine resistance in breast cancerThe Breast, 2011
- Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifenProceedings of the National Academy of Sciences, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Molecular Mechanisms of Tamoxifen Therapy for Cholangiocarcinoma: Role of CalmodulinClinical Cancer Research, 2009
- Cardiolipin provides an essential activating platform for caspase-8 on mitochondriaJournal of Cell Biology, 2008
- Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzinsJournal of Cell Biology, 2006
- A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinicCancer, 1991